Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$105,000.00
Design of a novel mutant human coagulation protein as a new anticoagulant drug, and as a tool for investigating the activity and regulation key enzymes in blood coagulation.
EF 2012-13
Résumé
Heart attacks and strokes, the number one cause of death and disability in Canada, are often caused by defective blood clotting in the human body. This research project aims to translate discoveries made on the scientific bench to the bedside, by figuring out the way blood clots are controlled in the body in order to identify novel therapeutic strategies.
In the past several years, numerous new anti-clotting drugs have entered the market worldwide for the treatment of strokes that target the blood clotting system. Unfortunately, given the biological nature of these new agents, readily accessible and effective antidotes and unavailable. This creates a major barrier to the widespread use of these easy to administer lifesaving drugs because for some patients, these drugs can cause life-threatening bleeding. These at-risk patients would need an antidote to quickly reverse their anticoagulation. Our laboratory has engineered a new molecule for which we have pilot data on a novel way to use this molecule to measure the action of the critical parts of the blood clotting system called tenase and prothrombinase. Because this part of the system is also the target for these new drugs, a clearer understanding of how they work aid in the development of an effective antidote for the new anti-clotting agents. Because our molecule also directly targets the tenase and prothrombinase systems, this new molecule or versions of it has the potential to become a new drug anti-clotting therapy for the treatment of heart attacks and stroke.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
283889
Name
Yeh Calvin H
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Design of a novel mutant human coagulation protein as a new anticoagulant drug, and as a tool for investigating the activity and regulation key enzymes in blood coagulation.
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Blood Coagulation Proteins; Enzyme Kinetics; Heparins And Other Anticoagulants ( Blood Thinners); Venous And Arterial Thromboembolism
Abstract
Heart attacks and strokes, the number one cause of death and disability in Canada, are often caused by defective blood clotting in the human body. This research project aims to translate discoveries made on the scientific bench to the bedside, by figuring out the way blood clots are controlled in the body in order to identify novel therapeutic strategies.
In the past several years, numerous new anti-clotting drugs have entered the market worldwide for the treatment of strokes that target the blood clotting system. Unfortunately, given the biological nature of these new agents, readily accessible and effective antidotes and unavailable. This creates a major barrier to the widespread use of these easy to administer lifesaving drugs because for some patients, these drugs can cause life-threatening bleeding. These at-risk patients would need an antidote to quickly reverse their anticoagulation. Our laboratory has engineered a new molecule for which we have pilot data on a novel way to use this molecule to measure the action of the critical parts of the blood clotting system called tenase and prothrombinase. Because this part of the system is also the target for these new drugs, a clearer understanding of how they work aid in the development of an effective antidote for the new anti-clotting agents. Because our molecule also directly targets the tenase and prothrombinase systems, this new molecule or versions of it has the potential to become a new drug anti-clotting therapy for the treatment of heart attacks and stroke.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Yeh, Calvin H
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~